1. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies
- Author
-
Lovelock, CE, Cordonnier, C, Naka, H, Al-Shahi Salman, R, Sudlow, Cathie, Sorimachi, T, Werring, DJ, Gregoire, SM, Imaizumi, T, Lee, SH, Briley, D, Jackson, Caroline Anne, Dennis, M, Wardlaw, Joanna M, Potter, Gillian Margaret, and Rothwell, PM
- Subjects
Male ,medicine.medical_specialty ,Brain Ischemia ,Brain ischemia ,Fibrinolytic Agents ,Risk Factors ,Internal medicine ,Antithrombotic ,Humans ,Medicine ,cardiovascular diseases ,Risk factor ,Contraindication ,Stroke ,Cerebral Hemorrhage ,Advanced and Specialized Nursing ,Intracerebral hemorrhage ,business.industry ,Warfarin ,Anticoagulants ,Odds ratio ,medicine.disease ,stroke ,intracerebral hemorrhage ,Surgery ,nervous system diseases ,warfarin ,microbleeds ,Female ,Neurology (clinical) ,antiplatelet agents ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background and Purpose— Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs. Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA). Methods— We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB. Results— In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3–3.5) in nonantithrombotic users to 5.7 (range, 3.4–9.7) in antiplatelet users and 8.0 (range, 3.5–17.8) in warfarin users ( P difference=0.01). There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6–4.4; P P =0.33; P difference=0.01). There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3–2.3; P P P difference=0.25). In pooled follow-up data for 768 antithrombotic users, presence of MB at baseline was associated with a substantially increased risk of subsequent ICH (OR, 12.1; 95% CI, 3.4–42.5; P Conclusions— The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH. Limited prospective data corroborate these findings, but larger prospective studies are urgently required.
- Published
- 2016